Objective: To investigate whether infliximab can be used in combination with cyclosporin A (CsA) in patients with refractory rheumatoid arthritis (RA) who cannot tolerate methotrexate (MTX). Materials and methods: Eighteen patients with refractory RA receiving low dose CsA (2 mg/kg/day) and prednisone (5 mg/day) were treated with intravenous infliximab. The patients were given infliximab (3 mg/kg weight) at 0, two, six, and every eight weeks thereafter for a total period of 12 months. Clinical improvement was evaluated according to the American College of Rheumatology (ACR) 20% response criteria. Results: Eighty per cent of patients receiving the combination treatment with CsA and infliximab achieved the 20% ACR criteria for response to treatment, whereas 39% satisfied the 50% response criteria. In addition, a 76% reduction in swollen and tender joint count was found. Finally, a reduction in C reactive protein and erythrocyte sedimentation rate was maintained throughout the study. In general, treatment was well tolerated, with minimal adverse drug reactions. Two patients dropped out; one because of an immediate hypersensitivity reaction and the other because of the development of pulmonary tuberculosis. Conclusion: Multiple infusions of infliximab and low doses of CsA improve patients with refractory RA. It seems that CsA may be an alternative disease modifying drug to be used in combination with infliximab in patients with refractory RA who cannot tolerate MTX. R heumatoid arthritis (RA) is a disease mediated by T cells, the initiation and perpetuation of which are dependent on the response of Th 1 lymphocytes to an as yet unknown antigen. 1 2 As a consequence of activation of Th 1 cells various cytokines are released, especially tumour necrosis factor α (TNFα) and interleukin 1 (IL1), resulting in chronic inflammatory synovitis, which leads to joint damage and bone destruction. 3 4 Patients with RA are usually treated with disease modifying antirheumatic drugs (DMARDs) until complete remission is reached. Unfortunately, complete remission occurs only in very few patients. 5 Thus, patients are given a combination treatment with two or more DMARDs simultaneously for a long period. 6 7 Blockage of TNFα is an effective targeted treatment which can modify the course of RA. 2 Infliximab is a chimeric IgG 1 monoclonal antibody that binds to cell bound and circulating TNFα and abrogates the biological effect of TNF. It has been approved to be used in combination with methotrexate (MTX) for patients who have continuous active RA despite adequate treatment with other DMARDs. 8 9 However, not all patients with RA can tolerate MTX and there have been no reports using infliximab with other DMARDs or DMARD combination treatment in patients with RA. Cyclosporin A (CsA), on the other hand, has been shown to be effective in the treatment of such patients 10 as well as in combination treatment with MTX in patients with refractory RA. 6 To investigate the efficacy, tolerability, and safety of infliximab in combination with CsA, we conducted a 12 month pilot study in patients with severe refractory RA.
MATERIALS AND METHODS

Study design
Eighteen patients who fulfilled the American College of Rheumatology (ACR) criteria for RA 11 were studied. The patients had had active disease for at least three months, were refractory to many DMARDs, and had discontinued MTX treatment because of various side effects. The current treatment was CsA and prednisone and despite this, the patients had active disease. We therefore investigated whether infliximab would provide additional clinical benefit to patients who had active RA. The patients were given intravenous infliximab (3 mg/kg) at 0, two, six, and every eight weeks thereafter for a total period of 12 months. At the time of the start of treatment the dose of CsA for each patient was 2 mg/ kg, the dose of prednisone 5 mg/day, and these remained stable during the study. The mean time of CsA treatment was 16.1 (SD 8.3) months, ranging from six to 41 months. During this treatment period CsA was well tolerated without serious adverse drug reactions. Patients were excluded from the study if they had (a) a history or presence of malignant diseases, (b) known liver or kidney abnormalities or history of viral hepatitis B and C, (c) major complicating diseases such as amyloidosis or heart or lung disease, (d) a positive tuberculin skin test using PPD/RT23 (2 IU/0.1 ml or abnormal chest radiograph suggesting chronic infectious disease, granulomatous disease, or other pathological findings.
Clinical assessment
Each patient underwent a complete physical examination before treatment and at each visit until the end of the study and every two months thereafter. Clinical disease variables included (a) duration of morning stiffness (minutes), (b) grip strength (mm Hg), (c) total joint count with tenderness or swelling, (d) number of swollen joints, (e) number of tender joints, (f) pain score (VAS; cm). Laboratory disease variables included C reactive protein (CRP; mg/l) and erythrocyte sedimentation rate (ESR; mm/1sth) that were performed at each patient's visit, which corresponded to infliximab infusion at weeks 0, two, six, and every eight weeks thereafter.
The clinical improvement was evaluated according to the ACR 20% response criteria. 
Definitions
A joint was defined as active if patients had synovitis with pain, swelling, and tenderness on pressure.
Disease was defined as active if patients had six or more active joints, high CRP (>10 mg/l), and high ESR (>40 mm/1sth).
Monitoring
A complete blood count with differential and platelet count, as well as serum values of liver enzymes, bilirubin, albumin, glucose, and creatinine, and urinary analysis were obtained before treatment and at each patient's visit, until the end of the study and every two months thereafter. Finally, 2 ml blood serum from patients (at each visit) were stored at -20°C for the measurement of autoantibody profile.
RESULTS
There were 15 women and three men with a mean age of 58.9 (SD 7.6) years and disease duration of 11.5 (SD 4.9) years. Eighty three per cent of patients were positive for rheumatoid factor and all were refractory to many DMARDs. The mean number of DMARDs received by our patients was 4 (SD 0.5). After treatment, most patients achieved a substantial clinical and laboratory response, as evaluated by the reduction of tender and swollen joints, by the reduction of pain score, and by the improvement of the global assessment judged by the physician. In addition, a decreased acute phase response was noted during the follow up period (table 1) . More specifically, 76.6% of patients had an improvement of swollen joints and 76% had improvement of tender joints. Also, 46% of patients showed a reduction in the pain score, whereas 39% presented improvement of the global assessment as it was evaluated by the physician (fig 1) . The clinical improvement was associated with a decrease in CRP and ESR of 71.5% and 38% respectively. Both clinical and laboratory improvement were evident after the first infusion of infliximab and the response increased with time (fig 1) . Thus, after 12 months of treatment, 80% of patients fulfilled the 20% ACR response criteria, and 39% satisfied the 50% response criteria (fig 2) . 13 Infliximab was well tolerated, with minimal adverse drug reactions. One patient developed acute aching, pain, and tingling affecting the legs, which occurred six hours after the fifth infusion. This side effect responded very well after 12 hours of treatment with diclofenac. Two more patients developed an upper respiratory tract infection after the fifth and sixth infusion respectively. Both responded very well to oral Results are given as mean (SD [range]); TJC, tender joint count; SJC, swollen joint count; ESR, erythrocyte sedimentation rate; CRP, C reactive protein; GAP, global assessment by physician; VAS, visual analogue score for pain measurement. *There were significant differences (p<0.001) between the first and last follow up in all variables studied. Figure 1 Response to combination treatment with infliximab and cyclosporin A. A reduction of 76% of swollen and tender joints was found, which was associated with a reduction in CRP and ESR of 71.5% and 38% respectively. Improvement of pain score and GAP were also noticed. TJC, tender joint count; SJC, swollen joint count; GAP, global assessment by a physician; ESR, erythrocyte sedimentation rate; CRP, C reactive protein, VAS, pain score.
erythromycin and antihistamines. In addition, two patients discontinued treatment. One stopped receiving infliximab after the fifth infusion owing to an immediate hypersensitivity reaction, which was manifested by redness of the face, dry cough, and mild dyspnoea. This patient responded well to intramuscular injections of antihistamines and hydrocortisone. The second patient was withdrawn from the study because of the development of pulmonary tuberculosis after the sixth infusion, despite the fact that she had a negative PPD skin test and normal chest radiograph. None of our patients developed hypertension requiring treatment and none had serum creatinine concentrations increased 30% above the baseline measurement. Finally, none developed clinical features or laboratory abnormalities suggesting systemic lupus erythematosus or other autoimmune diseases.
DISCUSSION
Studies have shown that infliximab is effective and safe in combination with MTX in patients with refractory RA. 8 9 However, not all patients tolerate MTX and there have been no reports using infliximab with other DMARDs in patients with RA. On the other hand, a recent study by Maini et al has shown that combined treatment with low dose CsA and anti-TNFα treatment caused a significant reduction in severity of disease in collagen induced arthritis, suggesting that CsA could be given in combination with anti-TNFα. 14 Thus the present study was designed to investigate the efficacy, tolerability, and safety of infliximab treatment in combination with CsA in patients with refractory RA who cannot tolerate MTX. We have treated severe, long standing mostly seropositive patients with RA.
Eighty per cent of our patients had a clinical response according to the ACR 20% criteria, 12 whereas 39% achieved the ACR 50% criteria. 13 The degree of improvement is particularly noteworthy in view of the inclusion of patients resistant to at least four DMARDs and with aggressive disease.
Infusions of infliximab were generally well tolerated. One patient developed pain and aching involving the legs and two developed infections in the upper respiratory tract. Two patients dropped out, one because of an immediate hypersensitivity reaction and another because of the development of chest tuberculosis, which probably represents a de novo tuberculosis infection, as our patients had a negative PPD test and normal chest radiograph before the start of of infliximab treatment. The absence of serious side effects with CsA is probably attributed to the low dose of CsA used and to the fact that none of our patients received non-steroidal antiinflammatory drugs, which may increase blood pressure and interfere with renal function. 10 These results are comparable with those reported in the studies of Maini et al and Lipsky et al in which they used infliximab in combination with MTX. 8 9 15 It seems that infliximab can be used safely with CsA. The combination of infliximab and CsA provides a strategy for future trials in RA to investigate whether anti-TNF treatment offers substantial progress in retarding the destructive disease process and improving the patients' quality of life.
Another factor to take into consideration is the development of antibodies against infliximab. Such antibodies developed in patients after repeated treatment with the drug. The incidence of this however, was reduced by concomitant treatment with MTX. 8 9 In the present study we do not yet know if the use of infliximab together with CsA may reduce the development of such antibodies. Serum samples from two patients who stopped receiving infliximab are now under investigation at the central laboratory of Schering Plough Pharmaceuticals in the United States.
This pilot study provides evidence that CsA may be an alternative DMARD, to be used in combination with infliximab in patients with refractory RA. However, double blind comparative studies with a large number of patients are needed to demonstrate the efficacy and safety of infliximab in combination with CsA.
